Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140028/S085

Innova Vascular Self-Expanding Stent System

BOSTON SCIENTIFIC CORPORATION · Decision date May 6, 2026

FDA DECISIONP140028/S085

What did the FDA decide?

FDA records P140028/S085 as a supplement to PMA P140028, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 6, 2026.

FDA approval order statement

the extension of maximum transfer time between preconditioning cell to sterilization chamber during routine production for Ethylene Oxide(EtO) sterilization
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
May 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P140028/S085
Regulatory pathway
PMA supplement
Product code
NIP
Decision code
OK30
Decision date
May 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.

Product code
NIP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P140028/S083 · Related supplement

    lnnova Vascular Self Expanding Stent

  2. P140028/S084 · Related supplement

    Innova Vascular Self-Expanding Stent System

  3. P140028/S085 received

    Application receipt date recorded by FDA.

  4. P140028/S085 · FDA decision

    30-Day Notice

  5. P140028/S087 · Related supplement

    Innova Self Expanding Stent System

  6. P140028/S088 · Related supplement

    Innova Vascular Self-Expanding Stent with Delivery System

Timeline entries are records held by MedtechLedger for P140028. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140028

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 8, 2025FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 24, 2025FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 6, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 21, 2026FDA

Explore the linked device profile

Other records with product code NIP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
One Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records